December 2, 2023
Headlines

Phase

Faron Broadcasts US Meals and Drug Administration and Finnish Medicines Company Approval to Provoke Part I/II Bexmarilimab Mixture Research in Hematologic Malignancies

Helena Musk015 mins

Faron Prescription drugs Ltd. (“Faron” or “Firm”) Faron Broadcasts US Meals and Drug Administration and Finnish Medicines Company Approval to Provoke Part I/II Bexmarilimab Mixture Research in Hematologic Malignancies Part 1 dose escalation research will consider the security and tolerability of mixture remedy and decide the advisable dose for Part 2 growth Affected person recruitment…

Read More

Moleculin Receives Approval from the UK’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) for Protocol Modification to Part 1a Scientific Trial of WP1122 for the Remedy of COVID-19

Helena Musk013 mins

– Dosing for first-in-human Part 1a research to judge security and pharmacokinetics of WP1122 in wholesome volunteers and set up most tolerated dose anticipated to start imminently – HOUSTON, Could 10, 2022 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Firm”), a medical stage pharmaceutical firm with a broad portfolio of drug candidates…

Read More

College of Tokyo, Astellas Enter Second Part of Strategic Partnership for Co-creation of Progressive New Medicines and Medical Options

Helena Musk09 mins

TOKYO, April 25, 2022 /PRNewswire/ — The College of Tokyo (President: Teruo Fujii, Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.; hereafter “Astellas”) entered the second section of their collaboration for co-creating progressive new medicines and medical options, referred to as the Astellas Alliance Acceleration Program (AAAP), right this moment….

Read More

Praxis Precision Medicines Reviews Unfavorable Outcomes from PRAX-114 Section 2/3 Monotherapy Aria Examine in Sufferers with Main Depressive Dysfunction

Helena Musk07 mins

Praxis Precision Medicines, Inc. Aria Examine didn’t obtain statistical significance on the first endpoint Strategic realignment to focus sources on Motion Issues and Epilepsy franchises extends money runway into 2024 BOSTON, June 06, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical firm translating genetic insights into the event of therapies…

Read More